Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Jun 15, 2020; 12(6): 642-650
Published online Jun 15, 2020. doi: 10.4251/wjgo.v12.i6.642
Clinical diagnosis and management of pancreatic mucinous cystadenoma and cystadenocarcinoma: Single-center experience with 82 patients
Zhi-Ming Zhao, Nan Jiang, Yuan-Xing Gao, Zhu-Zeng Yin, Guo-Dong Zhao, Xiang-Long Tan, Yong Xu, Rong Liu
Zhi-Ming Zhao, Nan Jiang, Yuan-Xing Gao, Zhu-Zeng Yin, Guo-Dong Zhao, Xiang-Long Tan, Yong Xu, Rong Liu, Second Department of Hepatopancreatobiliary Surgery, The First Medical Center of Chinese PLA General Hospital, Beijing 100853, China
Author contributions: Zhao ZM and Jiang N wrote the manuscript and contributed equally to this work and are co-first authors; Liu R conceived and designed the study; Jiang N, Gao YX, and Yin ZZ collected the data; Jiang N, Zhao GD, Tan XL, and Xu Y analyzed the data; all authors made critical revisions to the manuscript and approved the final version.
Institutional review board statement: The study was approved by the Institutional Review Board of the Chinese People's Liberation Army General Hospital (S2016-098-02).
Informed consent statement: Patients were not required to give informed consent to the study because the analysis used anonymous clinical data that were obtained after each patient agreed to treatment by written consent.
Conflict-of-interest statement: All authors declare no conflicts-of-interest related to this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Rong Liu, MD, PhD, Professor, Second Department of Hepatopancreatobiliary Surgery, The First Medical Center of Chinese PLA General Hospital, No. 28, Fuxing Road, Haidian District, Beijing 100853, China. liurong301@126.com
Received: April 30, 2020
Peer-review started: April 30, 2020
First decision: May 15, 2020
Revised: May 18, 2020
Accepted: May 21, 2020
Article in press: May 21, 2020
Published online: June 15, 2020
Core Tip

Core tips: In this study, we retrospectively analyzed the clinical and pathological records related with pancreatic mucinous cystadenoma (MCA) and mucinous cystadenocarcinoma (MCC). We found that the MCC tumor size was larger than that of MCA, and age, serum carcinoembryonic antigen, carbohydrate antigen (CA) 19-9, and CA12-5 levels were also higher in MCC patients. As the tumor size of MCA increased, the level of serum CA19-9 also increased. Surgical resection is the primary treatment for MCC and MCA.